hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06280014 id: YYU-09/15.12.2021 briefTitle: Evaluation of the Effects of Mefenamic Acid and Dexketoprofen on Postoperative Wisdom Dental Surgery overallStatus: COMPLETED date: 2022-01-20 date: 2022-02-20 date: 2023-09-25 date: 2024-02-28 date: 2024-02-28 name: Yuzuncu Yıl University class: OTHER briefSummary: This study was administered to 22 female and 8 male patients. Patients with impacted wisdom teeth on both sides of the mandible were selected. After impacted tooth extraction, the patient used mefenamic acid on one side and dexketoprofen on the other side for postoperative pain relief. The effects of these two materials on patient comfort were investigated. conditions: Tooth, Impacted conditions: Tooth Diseases studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: SUPPORTIVE_CARE masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 30 type: ACTUAL name: Surgery of impacted mandibular wisdom teeth name: Surgery of impacted mandibular wisdom teeth measure: Mouth opening measurements measure: Facial edema measure: Visual Analog Scale sex: ALL minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: Serap Keskin Tunc city: Van zip: 65100 country: Turkey lat: 38.49457 lon: 43.38323 hasResults: False
nctId: NCT06280001 id: 2023YFC2308802-04 briefTitle: A Multicenter Prospective Clinical Cohort Study on the Pathogen Spectrum of HIV/AIDS Complicated With Infection overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2026-11 date: 2026-11 date: 2024-02-28 date: 2024-03-04 name: Zhejiang University class: OTHER name: Beijing Ditan Hospital name: Beijing YouAn Hospital name: Huashan Hospital name: Qilu Hospital of Shandong University briefSummary: The goal of this observational study is to determine the incidence and spectrum of opportunistic infections among Chinese HIV/AIDS patients at this stage, to find intervention targets, to construct an early warning prediction model, and to give an individualized program with integrated immune function to obtain salvage opportunities for patients.The main questions it aims to answer are:
* Discover early warning and predictive markers and immunological indicators of pathogenic microorganisms, and explore new technologies and programs to reduce the mortality rate of infection. conditions: Acquired Immunodeficiency Syndrome conditions: HIV Infections studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 500 type: ESTIMATED measure: Secondary infections in patients with HIV/AIDS at 4 weeks measure: quick SEPSIS RELATED ORGAN FAILURE ASSESSMENT(qSOFA) at 4 weeks measure: Survival rate sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06279975 id: Req-2023-01275; am23Sutter2 briefTitle: Pupillometric Evaluation in Patients Declared Brain Dead - a Prospective Quality Control Study acronym: INSPECT overallStatus: RECRUITING date: 2023-12-18 date: 2029-12 date: 2030-12 date: 2024-02-28 date: 2024-02-28 name: University Hospital, Basel, Switzerland class: OTHER briefSummary: The aim of the study is to verify the reliability of the current purely clinical examination of the pupils (without the support of a pupillometer) in the context of clinically suspected brain death, compared to the results of a non-invasive, automated, and highly precise monocular pupillometric examination. conditions: Brain Death conditions: Adults studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 50 type: ESTIMATED name: non-invasive device-supported, automated pupillometry measure: Reliability of clinical examination of pupils in patients with suspected brain death sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Intensive care unit at the University Hospital Basel status: RECRUITING city: Basel state: Basel-Stadt zip: 4031 country: Switzerland name: Raoul Sutter, Prof. role: CONTACT phone: +41 61 328 7928 email: raoul.sutter@usb.ch name: Raoul Sutter, Prof. role: PRINCIPAL_INVESTIGATOR name: Pascale Grzonka, MD role: SUB_INVESTIGATOR lat: 47.55839 lon: 7.57327 facility: University Hospital Basel status: RECRUITING city: Basel country: Switzerland name: Raoul Sutter, Prof. role: CONTACT email: raoul.sutter@usb.ch name: Pascale Grzonka, MD role: CONTACT email: PascaleSusanne.Grzonka@usb.ch lat: 47.55839 lon: 7.57327 hasResults: False
nctId: NCT06279962 id: 2000034620 briefTitle: Survey Experiment to Estimate Level of Mental Illness Stigma Based on Condition and Gender overallStatus: COMPLETED date: 2023-06-15 date: 2023-09-15 date: 2023-09-15 date: 2024-02-28 date: 2024-02-28 name: Yale University class: OTHER name: Empower Through Health briefSummary: This study aims to measure levels of mental illness stigma based on condition and gender of the participants and individual portrayed with mental illness. conditions: Mental Illness conditions: Stigma, Social studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 379 type: ACTUAL name: Survey questionnaire measure: Level of acceptance for the individual depicted in the vignette as measured by PERSONAL ACCEPTANCE SCALE measure: Level of acceptance for the individual depicted in the vignette as measured by BROAD ACCEPTANCE SCALE sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Empowerment to Heal - Uganda city: Iganga country: Uganda lat: 0.60917 lon: 33.46861 hasResults: False
nctId: NCT06279949 id: 2000036999 id: 1K01MH136929-01 type: OTHER domain: NIMH *ID not yet added briefTitle: Confidential Care and Adolescent HIV Testing overallStatus: NOT_YET_RECRUITING date: 2026-04 date: 2027-10 date: 2027-10 date: 2024-02-28 date: 2024-02-28 name: Yale University class: OTHER name: National Institute of Mental Health (NIMH) briefSummary: The purpose of this study is to assess the feasibility and acceptability of structural intervention components to increase adolescent HIV testing uptake by improving the implementation of confidential care as standard practice in pediatric primary care. conditions: Hiv studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: FACTORIAL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 4 type: ESTIMATED name: Provider training name: Clinic protocols measure: Feasibility, defined as the extent to which structural intervention components to improve confidential care implementation can be successfully carried out in pediatric primary care settings measure: Acceptability, defined as the perception among pediatric primary care clinic leadership and providers that structural intervention components to improve confidential care implementation are agreeable or satisfactory measure: Change in HIV testing uptake measure: Reach, defined as the number of adolescent patients who receive confidential care measure: Adoption, defined as the proportion of pediatric primary care providers who have time alone with and/or provide confidentiality assurances to adolescent patients measure: Implementation, defined as pediatric primary care provider fidelity to confidential care provision measure: Maintenance, defined as the extent to which confidential care is provided and adolescent patients are screened for, accept, and receive results of HIV testing 6-months post-intervention sex: ALL minimumAge: 13 Years maximumAge: 17 Years stdAges: CHILD hasResults: False
nctId: NCT06279936 id: B3002021000171 briefTitle: Neurobiological Underpinnings of Neuropsychological Consequences in Long COVID acronym: Cov-N-Psy overallStatus: ACTIVE_NOT_RECRUITING date: 2021-11-01 date: 2023-12-31 date: 2024-12-31 date: 2024-02-28 date: 2024-02-28 name: Universiteit Antwerpen class: OTHER name: UZA Foundation briefSummary: Objectives:
The study is organized in three work packages (WP). WP1 includes a blood withdrawal and psychometric questionnaires and is part of every visit. WP2 includes cortisol measurement in saliva and takes place on the baseline visit for every participant and on the third visit for patients. Finally, WP3 includes a neurocognitive assessment at baseline for patients and Ca controls and on the third visit for patients. conditions: Long COVID studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 130 type: ACTUAL name: Neuropsychological battery name: Surveys and symptom severity questionnaires name: Blood withdrawal name: Saliva swabs measure: Concentration of immunological and HPA-axis markers measure: Rate of psychopathological and neurocognitive function of long COVID patients with neuropsychiatric complaints measure: Cross-sectional and longitudinal association between long COVID NP symptoms (BDI, HDRS, STAI, ISI, KEDS, FSS, NP battery ...) and immunological and cortisol measures (CAR, cytokines, serology, WBC, CRP, mitochondrial markers, TRYCATS, ...) sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: SINAPS city: Duffel state: Antwerp zip: 2570 country: Belgium lat: 51.09554 lon: 4.50903 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2022-10-01 uploadDate: 2024-02-08T04:56 filename: Prot_SAP_000.pdf size: 1140716 hasResults: False
nctId: NCT06279923 id: TXB2023023 briefTitle: CD19-BAFF CAR-T Cells Therapy for Patients With Autoimmune Diseases overallStatus: RECRUITING date: 2024-04-15 date: 2027-02-01 date: 2027-02-01 date: 2024-02-28 date: 2024-04-09 name: Zhejiang University class: OTHER name: Shanghai YaKe Biotechnology Ltd. briefSummary: Clinical Trial for the safety and efficacy of CD19-BAFF CAR-T cells therapy for Autoimmune Diseases. conditions: Autoimmune Diseases studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 45 type: ESTIMATED name: CD19-BAFF Targeted CAR T-cells measure: Dose-limiting toxicity (DLT) measure: Incidence of treatment-emergent adverse events (TEAEs) measure: Multiple Myeloma (MM), Overall response rate (ORR) measure: Progression-free survival (PFS) measure: Duration of remission,DOR sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The first affiliated hospital of medical college of zhejiang university status: RECRUITING city: Hangzhou state: Zhejiang zip: 310000 country: China name: He Huang, MD role: CONTACT phone: 86-13605714822 email: hehuangyu@126.com name: Yongxian Hu, MD role: CONTACT phone: +8615957162012 email: huyongxian2000@aliyun.com lat: 30.29365 lon: 120.16142 hasResults: False
nctId: NCT06279910 id: 2021 36 (EOm) briefTitle: Calcifediol in the Treatment of SARS-CoV-2 Disease (COVID-19). acronym: COVIDIOL overallStatus: RECRUITING date: 2024-02-21 date: 2024-03-21 date: 2024-04-25 date: 2024-02-28 date: 2024-02-28 name: Complejo Hospitalario Universitario de Albacete class: OTHER briefSummary: Descriptive, retrospective, observational, anonymous, study to evaluate the potential effect of incorporating calcifediol into the therapeutic protocol of patients hospitalized for COVID-19 on mortality and other outcome variables, such as admission to the Intensive Care Unit (ICU), to "Gerencia de Atención Integrada (GAI) de Albacete". "Complejo Hospitalario Universitario de Albacete". Albacete (Spain)", based on the files of the MXXI medical records, Information System of the Laboratory (ISL) and Pharmacy. conditions: SARS-CoV 2 Pneumonia studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 275 type: ESTIMATED name: Calcifediol measure: Measure mortality by differentiating groups: calcifediol yes/no. measure: Measure the need for ICU admission by differentiating the groups calcifediol yes/no. measure: Measure mortality in relation to baseline 25(OH)D levels measure: To evaluate the effect of calcifediol treatment on mortality in patients with severe 25(OH)D deficiency measure: Measure the composite variable poor prognosis, (death and ICU) by differentiating the groups calcifediol yes/no sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Complejo Hospitalario Universitario de la Gerencia de Atención Integrada (GAI) de Albacete status: RECRUITING city: Albacete zip: 02008 country: Spain name: Jose A Blazquez, MD role: CONTACT phone: +34967597100 phoneExt: 37214 email: jblazquez@sescam.jccm.es name: Laura Navarro, MD role: CONTACT phone: +34967597460 email: lnavarro@sescam.jccm.es name: Javier Torres, PhD. role: SUB_INVESTIGATOR lat: 38.99424 lon: -1.85643 facility: Maimónides Biomedical Research Institute of Córdoba (IMIBIC). status: WITHDRAWN city: Cordoba zip: 14004 country: Spain lat: 37.89155 lon: -4.77275 hasResults: False
nctId: NCT06279897 id: 2023-068 briefTitle: LBNP Tolerance With Skin Warming After Exercise Cold Stress overallStatus: RECRUITING date: 2022-01-24 date: 2025-09-30 date: 2025-09-30 date: 2024-02-28 date: 2024-02-28 name: University of Colorado, Colorado Springs class: OTHER briefSummary: Assess the effect of skin rewarming during lower body negative pressure upon arterial blood pressure and tolerance to simulated blood loss after exercise in the cold. conditions: Blood Pressure conditions: Blood Loss studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Participants will complete trial 1 at the beginning of the study. Participants will then complete trials 2 through 5 in a random, counterbalanced order. primaryPurpose: BASIC_SCIENCE masking: NONE maskingDescription: Participants are blinded to the skin temperature control. count: 10 type: ESTIMATED name: Skin Surface Rewarming name: Skin Surface Warming name: Skin Surface Heating name: Skin Surface Cooling measure: Arterial blood pressure measure: Tolerance to simulated blood loss measure: Core temperature measure: Cutaneous Vascular Conductance sex: ALL minimumAge: 18 Years maximumAge: 40 Years stdAges: ADULT facility: University of Colorado Colorado Springs status: RECRUITING city: Colorado Springs state: Colorado zip: 80918 country: United States name: James Pearson, PhD role: CONTACT phone: 719-255-3806 email: jpearso5@uccs.edu lat: 38.83388 lon: -104.82136 typeAbbrev: Prot_ICF hasProtocol: True hasSap: False hasIcf: True label: Study Protocol and Informed Consent Form date: 2023-01-03 uploadDate: 2024-02-22T15:33 filename: Prot_ICF_000.pdf size: 315418 hasResults: False
nctId: NCT06279884 id: 2023YFC2308802-03 briefTitle: A Cohort Study on the Pathogen Spectrum of Liver Transplant Recipients Complicated With Infection overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2026-11 date: 2026-11 date: 2024-02-28 date: 2024-03-04 name: Zhejiang University class: OTHER name: Beijing Ditan Hospital name: Beijing YouAn Hospital name: Huashan Hospital name: Qilu Hospital of Shandong University briefSummary: The goal of this observational study is to map the pathogen profile of secondary infections in liver transplant recipients, to correlate the basic immune status with the characteristics of the secondary infection pathogen profile, and to establish an early warning system for monitoring secondary infections, so as to explore safe and effective therapeutic modalities to further reduce the morbidity and mortality of liver failure. The main questions it aims to answer are:
* Establish a monitoring and early warning system for secondary infections. conditions: Liver Transplantation conditions: Transplant Recipients studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 1000 type: ESTIMATED measure: Secondary Infections in liver transplant recipients at 4 weeks measure: quick SEPSIS RELATED ORGAN FAILURE ASSESSMENT(qSOFA) at 4 weeks measure: Occurrence of secondary infections in liver transplant recipients at 8 weeks, including site of infection, pathogen of infection measure: Occurrence of secondary infections in liver transplant recipients at 12 weeks, including site of infection, pathogen of infection measure: qSOFA score at 8 weeks measure: qSOFA score at 12 weeks sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06279871 id: ARCT-2303-01 briefTitle: Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-10 date: 2024-12 date: 2024-02-28 date: 2024-02-28 name: Arcturus Therapeutics, Inc. class: INDUSTRY name: Seqirus name: Novotech (Australia) Pty Limited briefSummary: This is a multicenter, observer-blind, randomized, controlled phase 3 study to evaluate the immunogenicity, reactogenicity, and safety of an investigational self-amplifying RNA COVID-19 vaccine (ARCT-2303) administered concomitantly with quadrivalent influenza vaccines or standalone in adults who previously received authorized COVID-19 vaccine. conditions: COVID-19 studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 1680 type: ESTIMATED name: ARCT-2303 name: Influenza vaccine name: Influenza vaccine, adjuvanted name: Placebo measure: SARS-CoV-2 neutralizing antibody titers measure: SARS-CoV-2 neutralizing antibody seroconversion rates measure: Hemagglutination Inhibition (HI) titers measure: SARS-CoV-2 neutralizing antibody titers measure: SARS-CoV-2 neutralizing antibody titers measure: SARS-CoV-2 neutralizing antibody seroconversion rates measure: SARS-CoV-2 neutralizing antibody response (Group 1a; Group 2a) measure: Hemagglutination Inhibition (HI) titers measure: SARS-CoV-2 neutralizing antibody responses measure: Hemagglutination Inhibition (HI) assay titers measure: Local and systemic adverse events (AEs) measure: Unsolicited AEs measure: SAE, Medically Attended Adverse Events (MAAE), Adverse Events of Special Interest (AESI), and AE leading to early termination sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06279858 id: 1-2024 briefTitle: Probiotic Intervention for Microbiome Modifications and Clinical Improvements in Fragile X Syndrome overallStatus: RECRUITING date: 2024-01-01 date: 2024-12-31 date: 2024-12-31 date: 2024-02-28 date: 2024-02-28 name: Specila hospital for cerebral palsy and developmental neurology class: OTHER name: FRAXA Research Foundation briefSummary: The primary objective of this clinical trial is to evaluate efficacy of probiotic mixture which contains Lactobacillus casei, Lactobacillus salivarius and Bifidobacterium breve, in children with Fragile X aged 3-18 years. Specifically, links between microbiome modifications by probiotic mixture and behavioral manifestations and brain processing (eye tracker, EEG analysis) will be assessed. Exploratory objects of this trial are analyses of microbiome composition and assessment of its alterations and modifications (by probiotic mixture) that may lead to clinical improvement and prediction which patients with FXS may be likely to benefit from probiotics treatment.
This is open label trial without masking, where each participant receives probiotic for 3 months (12 weeks). It will be single group assignment. The study plans to enroll 15 participants with FXS, aged 3-18 years, both sexes, during 1-year period and complete all study-related activities by January 2025. During the 3-month study period, subjects will attend three visits (screening/baseline, 6-week, and 3-month visits) to the Fragile X Clinic at the Special Hospital for Cerebral Palsy and Developmental Neurology, Belgrade, Serbia. The primary outcome measureswill be Vineland Adaptive Behavior Scales-Third Edition (VABS-III) and eye tracking measures (social gaze and pupillometry). Exploratory endpoint will be microbiome analyses. Secondary outcome measures will be: CGI-S and CGI-I scores, ABC-CFX score, quality of life, sleep habits and EEG analyses. conditions: Fragile X Syndrome studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: This is open label trial without masking, where each participant receives probiotic for 3 months (12 weeks). It will be single group assignment. In this approach, participants act as their own controls by measuring the microbiome and other parameters before and after taking the probiotics. This design was chosen because individual's microbiome is highly personalized. Even within a family, individuals can have distinct microbiomes. The unique composition of an individual's microbiome can have implications for the effectiveness of probiotics. Thus, changes in analyses and scores between baseline and 3-month study period will be assessed for everyone. Specifically, microbiome modifications that may be associated with changes in behavior and brain processing will be examined. primaryPurpose: BASIC_SCIENCE masking: NONE count: 15 type: ESTIMATED name: Probiotics measure: 1. Vineland Adaptive Behavior Scales-Third Edition (VABS-III) measure: Eye tracking measure: Clinical Global Impression Scales of Severity (CGI-S) and Improvement (CGI-I) - measure: The Aberrant Behavior Checklist - Community Edition (ABC-C), scored using the FXS-specific factoring system (ABC-CFX) measure: Pediatric Quality of Life Questionnaire (PedsQL) Parent Proxy measure: Child Sleep Habits Questionnaire (CSHQ) measure: EEG analyses measure: Microbiome analyses sex: ALL minimumAge: 3 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Special Hospital for Cerebral Palsy and Developmental Neurology status: RECRUITING city: Belgrade zip: 11000 country: Serbia name: Dragana Protic, Prof. role: CONTACT phone: +381640667466 email: dragana.protic@sbcprn.com name: Sanja Dimitrijevic, PhD role: CONTACT phone: +381640667466 email: sanja.dimitrijevic@sbcprn.com lat: 44.80401 lon: 20.46513 hasResults: False
nctId: NCT06279845 id: 2023YFC2308802-02 briefTitle: A Clinical Cohort Study on the Pathogen Spectrum of Hepatic Virus-caused Cirrhosis Complicated With Infection overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2026-11 date: 2026-11 date: 2024-02-28 date: 2024-03-04 name: Zhejiang University class: OTHER name: Beijing Ditan Hospital name: Beijing YouAn Hospital name: Huashan Hospital name: Qilu Hospital of Shandong University briefSummary: The goal of this observational study is to expound the population and characteristics of pathogenic microorganisms with co-infection, draw the pedigree of pathogenic microorganisms, and evaluate its influence on disease outcome in patients with hepatic virus-caused cirrhosis. The main questions it aims to answer are:
* Map the spectrum of pathogenic microorganisms, and evaluate their impact on disease regression. conditions: Liver Cirrhosis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 2000 type: ESTIMATED measure: Secondary infection in patients at 4 weeks measure: quick SEPSIS RELATED ORGAN FAILURE ASSESSMENT(qSOFA) at 4 weeks measure: Survival rate sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06279832 id: 3994 briefTitle: Radiomics and Radiogenomics Models to Predict Molecular Integrated Risk Classes and Prognostic Factors in Endometrial Cancer. acronym: Romantic overallStatus: RECRUITING date: 2023-11-01 date: 2024-10-31 date: 2025-10-31 date: 2024-02-28 date: 2024-02-28 name: Fondazione Policlinico Universitario Agostino Gemelli IRCCS class: OTHER briefSummary: The aim is to develop radiogenomics models to stratify patients into three main risk categories (Favorable, Intermediate, and Unfavorable) according to the ProMisE model (9) and use these models to predict the most prognostically relevant EC histopathological features (i.e. FIGO stage, degree of tumor differentiation, histotype, LVSI status, myometrial and cervical invasion, lymph node metastases).